Kazia Therapeutics Limited EBIT

Kazia Therapeutics Limited (KZIA) currently reports a EBIT of $-42M as of December 2025. That compares with $-40M in the prior-year period — down 6.4% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Kazia Therapeutics Limited's EBIT history and peer comparisons.

Kazia Therapeutics Limited's EBIT decreased from $-40M to $-42M — a 6.4% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kazia Therapeutics Limited's EBIT of $-42M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Kazia Therapeutics Limited reported $-42M in EBIT as of December 2025. That compares with $-40M in the prior-year period — down 6.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-42M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Kazia Therapeutics Limited, and consider following KZIA for alerts when major investors trade the stock.